Voriconazole — Why It Is Dangerous, Side Effects and Contraindications

EFFECTIVE | TOXIC

Names Under Which Voriconazole Is Available: The international nonproprietary name is voriconazole, the Latin spelling is Voriconazole, and the pharmacopoeial form is Voriconazolum. The active substance is used without a separate pharmaceutical salt. The main dosage forms are tablets, powder for oral suspension, and a lyophilizate or powder for preparing a solution for intravenous infusion. The original brand name is Vfend; generic products are also registered in different countries under the names Voriconazole Accord, Voriconazole Sandoz, and other trade names containing the word Voriconazole. Standard fixed-dose combinations in which voriconazole is combined with another antifungal agent in a single dosage form are practically not used. However, hidden pharmacological duplication is possible if a patient receives voriconazole tablets, suspension, and the intravenous formulation at the same time or independently adds another systemic azole antifungal. Voriconazole must not be confused with fluconazole, itraconazole, posaconazole, or isavuconazole: these are different substances, but combining them can sharply alter drug concentrations and the toxicological profile.

Why Voriconazole Is Considered an Ordinary Antifungal Drug and Where the Real Risk Begins: Voriconazole is intended primarily for the treatment of severe invasive mycoses, not for self-treatment of skin or nail candidiasis or a nonspecific coating on the tongue. Its main problem is its nonlinear and highly variable pharmacokinetics: the same dose can produce substantially different concentrations in different patients. Drug levels depend on the genetically determined activity of CYP2C19, liver function, age, inflammation, food intake, and numerous drug interactions. Higher concentrations are associated with a greater likelihood of liver injury, visual disturbances, and neuropsychiatric disorders. Therefore, the absence of toxicity after the first few doses does not guarantee that the concentration will not become dangerous later.

A false sense of safety arises because the drug is available in tablet form and appears no different from an ordinary outpatient medication. In reality, voriconazole can cause hepatitis, cholestasis, fulminant liver failure, QT prolongation, ventricular arrhythmias, severe skin reactions, phototoxicity, visual disturbances, and toxic reactions affecting the central nervous system. In clinical trials, the most common reaction was visual disturbance, reported in approximately 18.7% of adults; elevated liver test results, rash, and visual disturbances were among the most frequent reasons for discontinuation.

Short-Term Side Effects: During the first hours after a dose, blurred vision, altered colour perception, photophobia, a sensation of flashing lights, increased brightness of light, and reduced visual adaptation in the dark may occur. These reactions often develop shortly after a dose and may recur after every administration. Until the individual response is known, driving, working at night, and activities requiring precise visual coordination are dangerous. With substantial exposure, visual or auditory hallucinations, agitation, confusion, insomnia, anxiety, dizziness, ataxia, and, less commonly, seizures may occur.

Common reactions include nausea, vomiting, diarrhoea, abdominal pain, headache, fever, and skin rash. Rapid elevations in ALT, AST, alkaline phosphatase, and bilirubin, drug-induced hepatitis, cholestatic jaundice, acute kidney injury, hypokalaemia, hypomagnesaemia, and hypocalcaemia are clinically significant. Electrolyte disturbances increase the likelihood of QT prolongation and torsades de pointes polymorphic ventricular tachycardia. The risk is particularly increased when voriconazole is combined with cardiotoxic drugs and in patients with bradycardia, cardiomyopathy, or pre-existing QT prolongation.

Life-threatening reactions include anaphylaxis, airway oedema, Stevens–Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome, fulminant liver failure, and severe ventricular arrhythmia. Intravenous administration may cause infusion reactions accompanied by flushing, sweating, chest tightness, shortness of breath, nausea, and reduced blood pressure. The development of a widespread rash, blisters, epidermal detachment, mucosal lesions, jaundice, fainting, or palpitations requires immediate discontinuation of the infusion and urgent medical assessment.

Side Effects During Long-Term or Repeated Use: Prolonged treatment produces a distinct toxicity profile. Phototoxic reactions may manifest as severe sunburn, erythema, cheilitis, pseudoporphyria, lentigines, and damage to exposed areas of the skin. When treatment has been continued despite photodamage, precancerous changes, cutaneous squamous cell carcinoma, Bowen disease, and melanoma have been reported. Therefore, long-term use without strict photoprotection and dermatological monitoring cannot be considered acceptable. Children’s skin is particularly sensitive, and photodamage may require monitoring even after the drug has been discontinued.

With treatment lasting several months, fluoride accumulation, periostitis, and skeletal fluorosis may occur. Clinically, these conditions present with diffuse pain in the bones, ribs, shoulder girdle, and pelvic girdle, restricted movement, periosteal tenderness, and elevated alkaline phosphatase. The changes may partially regress after discontinuation, but recovery can be slow. Persistent visual disorders, optic neuritis, and optic disc oedema have also been reported during post-marketing surveillance.

Hepatotoxicity may develop both at the beginning of treatment and after several weeks. It ranges from asymptomatic elevation of transaminases to clinical hepatitis, cholestasis, and acute liver failure. Recovery after discontinuation often takes one to three months, while liver transplantation and fatal outcomes have been reported in severe cases. The absence of elevated enzymes during the first few days does not exclude subsequent injury.

Voriconazole does not cause classic drug dependence or a typical withdrawal syndrome. However, a prolonged course may mask a persistent focus of infection, while premature discontinuation creates a risk of recurrence, dissemination of the mycosis, and selection of a resistant pathogen. When combined with systemic or inhaled corticosteroids, Cushing syndrome and subsequent adrenal insufficiency may occur because steroid metabolism is inhibited.

Contraindications and High-Risk Groups: A confirmed hypersensitivity to voriconazole or any excipient is an absolute contraindication. A cross-reaction is possible in patients allergic to other azole antifungals, although its probability has not been precisely established. Tablet formulations containing lactose are contraindicated in certain rare hereditary disorders of galactose metabolism and in glucose-galactose malabsorption.

During pregnancy, voriconazole can harm the foetus and is used only for a life-threatening infection when the expected benefit outweighs the risk. Women of reproductive age require effective contraception. Patients with liver disease have increased systemic exposure: in moderate hepatic impairment, the area under the pharmacokinetic curve after a single dose was approximately 3.2 times higher than in individuals with normal liver function. No reliable dose-adjustment regimens are available for severe cirrhosis.

The drug is particularly dangerous in patients with congenital or acquired QT prolongation, cardiomyopathy, marked bradycardia, heart failure, hypokalaemia, hypomagnesaemia, or hypocalcaemia. Such patients have an increased risk of torsades de pointes and sudden cardiac death. Oral voriconazole does not require standard dose adjustment in renal impairment, but the intravenous formulation contains the cyclodextrin carrier SBECD, which may accumulate when glomerular filtration is reduced; in addition, acute kidney injury has also been reported during treatment itself.

Patients after transplantation, individuals with haematological malignancies, children, older adults, patients with marked systemic inflammation, low body weight, or concomitant polypharmacy have an increased risk of toxicity. Hepatic laboratory abnormalities and phototoxic reactions were observed more frequently in children than in adults. Drug concentrations may be higher in older adults, although automatic dose adjustment based solely on age is not formally recommended.

Dangerous Interactions: Voriconazole is both a substrate and an inhibitor of CYP2C19, CYP2C9, and CYP3A4. Therefore, some drugs sharply reduce its concentration and make treatment ineffective, while others increase voriconazole levels or themselves accumulate to toxic concentrations. The complete medication list must be reviewed before the first dose and whenever therapy is changed.

Combinations with rifampicin, rifabutin, carbamazepine, long-acting barbiturates, and St John’s wort are contraindicated: CYP450 induction lowers the concentration of voriconazole and creates a risk of treatment failure. A course of St John’s wort reduced the systemic exposure of voriconazole by approximately 59%. Standard regimens containing high doses of efavirenz or ritonavir are contraindicated; low doses of ritonavir should also preferably be avoided.

Because of the risk of QT prolongation and torsades de pointes, pimozide, quinidine, and ivabradine are contraindicated. Concomitant use with sirolimus is contraindicated because of the sharp increase in its concentration. Ergotamine and dihydroergotamine are also contraindicated because of the risk of ergotism, naloxegol because it may provoke opioid withdrawal, as well as tolvaptan, lurasidone, finerenone, and certain stages of venetoclax treatment.

Concomitant use with fluconazole should be avoided: fluconazole increased the maximum concentration of voriconazole by approximately 57% and systemic exposure by approximately 79%; dose reduction did not eliminate the interaction. Phenytoin lowers the concentration of voriconazole, but phenytoin itself may accumulate under its influence, so this combination requires dose adjustment and therapeutic monitoring. Letermovir reduces voriconazole exposure and may lead to an inadequate antifungal effect.

Voriconazole substantially increases the concentrations of tacrolimus, ciclosporin, warfarin, certain statins, benzodiazepines, sulfonylureas, vinca alkaloids, methadone, and oxycodone. Tacrolimus exposure may increase approximately threefold, and oxycodone exposure by more than threefold. Possible consequences include nephrotoxicity, neurotoxicity, bleeding, rhabdomyolysis, profound sedation, respiratory depression, and QT prolongation. Ibuprofen and diclofenac may also accumulate: systemic exposure to the active isomer of ibuprofen increased approximately twofold. These combinations require a reduction in the dose of the relevant drug and laboratory monitoring.

Combining voriconazole with corticosteroids can cause hypercortisolism, Cushing syndrome, and subsequent adrenal insufficiency. Alcohol is not identified in the prescribing information as a specifically contraindicated pharmacokinetic combination. However, in the presence of hepatotoxicity, dizziness, visual disturbances, and neuropsychiatric reactions, its use is clinically unreasonable: it increases the burden on the liver and may worsen impaired coordination and consciousness. This is a clinical conclusion based on the toxicity profile, not a proven specific interaction.

Patient Errors: The most dangerous mistake is self-prescribing voriconazole for any suspected fungal infection without microscopy, culture, pathogen identification, and susceptibility testing. The drug is not intended for empirical treatment of ordinary skin itching, nail changes, white coating, or discharge without confirmation of an invasive or severe mycosis. Such treatment creates a toxicological burden and may at the same time be ineffective against the specific pathogen.

The dose must not be increased in the absence of rapid improvement: voriconazole has nonlinear pharmacokinetics, so even a small increase in dose can cause a disproportionate rise in concentration. Shortening the dosing interval, taking another dose after vomiting without medical advice, switching between tablets, suspension, and the infusion formulation without recalculation, and combining voriconazole with fluconazole or another azole drug are dangerous.

Another common mistake is failing to tell the physician about St John’s wort, anticonvulsants, post-transplant medicines, antiarrhythmics, anticancer drugs, analgesics, and hormonal medicines. St John’s wort is often perceived as a harmless herbal antidepressant, but it can sharply lower the concentration of voriconazole. It is equally dangerous to ignore photosensitivity and continue spending time in the sun: repeated phototoxic injuries are associated with a risk of precancerous and malignant skin changes.

Stopping treatment independently after fever decreases or well-being improves is also a mistake. In invasive aspergillosis and other deep mycoses, clinical improvement does not mean eradication of the pathogen. On the other hand, continuing treatment for months without monitoring the drug concentration, liver and kidney function, electrolytes, skin, vision, and bone pain is equally dangerous.

Overdose and Poisoning: The exact single toxic dose of voriconazole in humans has not been established. Three accidental overdoses were reported in clinical trials in children who received up to five times the recommended intravenous dose; the documented reaction was photophobia lasting approximately ten minutes. These observations do not prove the safety of a fivefold dose: the number of cases was too small, and voriconazole toxicity depends not only on the dose but also on liver function, CYP2C19 genotype, drug interactions, and the patient’s baseline condition.

Poisoning may manifest as an intensification of characteristic dose-dependent reactions: severe photophobia, blurred vision, visual phenomena, hallucinations, confusion, ataxia, headache, nausea, vomiting, diarrhoea, tachycardia, and abnormal liver test results. In severe intoxication, seizures, marked QT prolongation, ventricular arrhythmia, acute liver injury, and acute kidney injury must be considered. Symptoms may be nonspecific, and laboratory evidence of liver injury may appear after the initial deterioration in well-being.

A hidden overdose may occur when the dosing interval is shortened, the suspension is prepared incorrectly, a paediatric dose is miscalculated, several dosage forms are used simultaneously, hepatic clearance is reduced, or voriconazole is combined with CYP inhibitors. Concomitant use with fluconazole and drugs that increase voriconazole concentration is particularly dangerous. If overdose is suspected, one must not wait for jaundice, arrhythmia, or impaired consciousness to develop.

There is no specific antidote. Treatment includes stopping further exposure to the drug, urgent assessment of the ECG, electrolytes, liver and kidney function, and symptomatic and supportive therapy. Voriconazole and the intravenous carrier SBECD are removed by haemodialysis; in severe poisoning or renal failure, haemodialysis may promote their elimination, but it does not replace intensive monitoring.

Safe Integrative Alternative for Localised Mycoses: Voriconazole must not be mechanically replaced with herbal remedies in invasive aspergillosis, candidaemia, severe systemic candidiasis, or fungal infection of the lungs, central nervous system, or internal organs. It is intended primarily for severe and potentially life-threatening infections caused by Aspergillus, Candida, Scedosporium, and Fusarium. In such diseases, a systemic concentration of the antifungal agent is required, which local formulations cannot provide.

The situation is different in superficial mycoses of the skin, nails, external auditory canal, nasal cavity, and oropharynx. Prescribing systemic voriconazole for a localised process without signs of invasion often creates a disproportionate toxicological burden: the drug affects the entire body even though the focus of infection is accessible to direct local treatment. In such cases, a site-oriented regimen is appropriate because it allows high concentrations of active components to be created directly at the focus while reducing exposure of the liver, cardiac conduction system, nervous system, vision, and skin.

For mycoses of smooth skin, skin folds, feet, and interdigital spaces, an antifungal spray may be used. The liquid formulation is convenient for extensive, moist, and hard-to-reach areas. For dense, dry lesions and involvement of the periungual folds and nail plates, an antifungal ointment is preferable because it provides more prolonged contact with the surface. Such topical therapy does not replace a systemic antifungal when the infection has penetrated deep tissues, but in a limited superficial process it allows unjustified use of voriconazole to be avoided.

As a systemic herbal component of the regimen, Indian neem — Azadirachta indica may be considered. Its use is pharmacologically justified in superficial and recurrent fungal processes as an adjunct to local decontamination, especially when it is necessary to act simultaneously on inflammation and microbial-fungal colonisation. However, neem must not be presented as an equivalent replacement for voriconazole in invasive aspergillosis or fungaemia: it does not have comparable proven systemic efficacy in life-threatening mycoses.

For fungal involvement of the nasal cavity, upper respiratory tract, external ear, and oropharyngeal mucosa, ABP-153 is used locally: intranasally, in the external auditory canal, and for application to the mucous membrane of the throat. This formulation allows direct treatment of the affected surface. Before treating the ear, perforation of the tympanic membrane, otitis media, and invasive spread of infection must be excluded. In fungal sinusitis with tissue necrosis, orbital involvement, severe unilateral pain, black crusts, or neurological symptoms, local therapy is unacceptable as the sole treatment method.

For candidiasis and mixed inflammatory-fungal lesions of the oral mucosa, an oral gel may be used. The mucoadhesive formulation keeps the components on the mucosa longer than ordinary rinsing. In diffuse oral involvement, coating, erosions, gingival inflammation, and when a large area requires treatment, Thai FD oral powder is used. These formulations should be combined with correction of factors promoting recurrence: mucosal dryness, inadequately cleaned dentures, inhaled glucocorticosteroids, uncontrolled hyperglycaemia, and unjustified courses of antibiotics.

ABP-153D may be included as an additional component in marked inflammation, tissue damage, and persistent pain. It is not the primary antifungal and must not replace pathogen diagnosis or targeted antifungal treatment.

Thus, complete replacement of voriconazole is possible not with a “herbal analogue of voriconazole,” but by refusing unjustified systemic treatment where the fungal process is superficial and accessible to local therapy. In invasive mycosis, voriconazole or another systemic antifungal remains necessary; in this situation, integrative products may be used only as adjuncts and must not delay specialised treatment.

The Real Effectiveness of Voriconazole and Errors in Medical Prescribing: Voriconazole is genuinely effective in invasive aspergillosis, candidaemia in patients without neutropenia, severe invasive Candida infections, including some fluconazole-resistant strains, oesophageal candidiasis, and severe infections caused by Scedosporium and Fusarium. The drug disrupts the formation of ergosterol, a structural component of the fungal membrane, thereby suppressing growth or causing the death of a susceptible pathogen.

In invasive aspergillosis, it is prescribed not for temporary suppression of symptoms but to act on the cause of the disease. Clinical improvement may manifest as reduced fever, less respiratory failure, stabilisation of pulmonary lesions, and cessation of dissemination, but the speed of response depends on immune status, infection site, and extent of involvement. The disappearance of fever or cough does not prove eradication of the fungus: radiological changes may persist or initially even increase during immune recovery.

Voriconazole is not a rational first-line drug for ordinary interdigital mycosis, limited cutaneous candidiasis, uncomplicated onychomycosis, fungal otitis externa, or unconfirmed “fungus in the body.” Prescribing a systemic triazole with nonlinear pharmacokinetics, hepatotoxicity, and dozens of clinically significant interactions for a superficial focus is not “strong treatment,” but a toxicologically costly substitute for diagnosis.

Common medical errors include prescribing without microscopy, culture, histology, or antigen testing; failure to identify the pathogen; ignoring possible resistance; use in colonisation without proven infection; failure to review interactions and obtain a baseline ECG; and prescribing to a patient with uncorrected hypokalaemia or severe liver injury. Continuing treatment at a toxic concentration merely because the prescribed dose formally complies with the instructions is also an error. Because of variable pharmacokinetics, the same dose does not mean the same exposure in different patients.

Safety Monitoring During Treatment: Before therapy begins, ALT, AST, alkaline phosphatase, total and direct bilirubin, creatinine, estimated glomerular filtration rate, potassium, magnesium, and calcium must be determined. An ECG is required in patients with cardiovascular disease, fainting, bradycardia, baseline QT prolongation, or concomitant use of drugs affecting repolarisation. Electrolyte disturbances must be corrected before treatment because they increase the risk of ventricular arrhythmias.

Liver function must be monitored at least weekly during the first month and then regularly throughout treatment if the results remain stable. More frequent monitoring is required in patients with pre-existing hepatic impairment, elevated transaminases, jaundice, or concomitant use of other hepatotoxic drugs. A significant and progressively worsening elevation of liver test results that cannot be explained by the infection or another disease requires reassessment of therapy and usually discontinuation of voriconazole.

Therapeutic drug monitoring of voriconazole concentration is advisable in severe infection, prolonged treatment, lack of response to a standard dose, suspected toxicity, liver disease, treatment of children, polypharmacy, or use of interacting medicines. It helps distinguish inadequate exposure from pathogen resistance and toxic exposure from nonspecific deterioration in the patient’s condition.

Visual and neuropsychiatric reactions must be monitored during treatment. Transient visual phenomena are common, but persistent loss of vision, eye pain, visual field defects, colour vision abnormalities, or prolonged photophobia require ophthalmological assessment. If therapy lasts longer than several weeks, exposed areas of the skin must be examined regularly. Severe phototoxicity, persistent erythema, a non-healing erosion, induration, or a change in a pigmented lesion requires dermatological assessment because of the reported risk of precancerous changes and skin cancer.

During prolonged treatment, patients should be asked about diffuse pain in the bones, ribs, shoulders, and pelvic girdle. When combined with elevated alkaline phosphatase, these symptoms may indicate periostitis or skeletal fluorosis. During intravenous administration in the presence of renal impairment, accumulation of the excipient SBECD must be considered, and the patient should be switched to an oral formulation as soon as the clinical condition permits.

Fainting, marked palpitations, seizures, impaired consciousness, hallucinations with disorientation, difficulty breathing, swelling of the face or larynx, jaundice, dark urine, a sharp decrease in urine output, a widespread painful rash, blisters, skin detachment, or mucosal involvement require immediate discontinuation of the drug and emergency medical care. Waiting for the results of a scheduled laboratory test in such situations may allow progression of liver failure, arrhythmia, anaphylaxis, or a severe skin reaction.

Correct Discontinuation of Voriconazole: Voriconazole does not cause classic physical dependence, so gradual dose reduction to prevent a withdrawal syndrome is usually unnecessary. If a toxic reaction develops, the drug is stopped immediately while the severity of the fungal infection and the need to switch to another systemic antifungal are assessed.

The absence of a withdrawal syndrome does not mean that the drug can be stopped independently after the patient feels better. In invasive mycosis, premature discontinuation may lead to recurrence, dissemination of the infection, involvement of the central nervous system, and formation of a resistant fungal population. The duration of treatment is determined by the clinical response, immune status, results of mycological testing, and imaging dynamics, not solely by disappearance of fever.

A missed dose must not be compensated for by doubling the next dose. When switching from intravenous administration to tablets or suspension, bioavailability, body weight, age, liver function, and drug interactions must be considered. Independently replacing voriconazole with another azole is also dangerous: the drugs differ in their spectrum of activity, pharmacokinetics, dosing, and interaction profile.

Special attention is required when discontinuing concomitant corticosteroids. Voriconazole can inhibit their metabolism and cause iatrogenic hypercortisolism; adrenal insufficiency may become apparent after the combined regimen is changed. Therefore, a corticosteroid used for a long period must not be stopped abruptly solely because voriconazole has been discontinued.

A Rational Approach to the Use of Voriconazole: Voriconazole is justified when the infection is invasive, rapidly progressive, threatens internal organs or life, and the pathogen falls within the drug’s spectrum of activity. Under these circumstances, its high systemic activity is more important than its potential toxicity, but only with laboratory, clinical, and medication monitoring.

For superficial fungal infections of the skin, nails, external ear, nasal cavity, or oral mucosa, systemic voriconazole is usually disproportionate to the clinical task. It is more rational to use local treatments: an antifungal spray, antifungal ointment, ABP-153, an oral gel, and Thai FD oral powder, supplemented when necessary with Azadirachta indica and ABP-153D.

The purpose of an integrative approach is not to reject a potent antifungal where it saves lives, but to stop its unjustified use in localised diseases. This reduces hepatotoxicity, phototoxicity, the risk of drug interactions, rhythm disturbances, and delayed complications without reducing the quality of treatment for a correctly diagnosed superficial mycosis.

If you have questions about the subject of this article, you can ask a clinical pharmacologist in the comments or book an appointment using this link: https://asiabiopharm.com/konsultaciii/